Source-grounded facts extracted from Vivos Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 17, 2026, Vivos Therapeutics, Inc. (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholde”
Vivos Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $17.5 million.
“Revenue was $17.5 million for the year ended December 31, 2025, compared to $15.0 million for the full year ended December 31, 2024, a year over year increase of 16%.”
Vivos Therapeutics, Inc. entered into Securities Purchase Agreement with V-Co Investors 3 LLC valued at $850,000 cash proceeds; $1,400,000 conversion of bridge note; total purchase price $1.34 per share (effective 2026-03-31).
“On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).”
Vivos Therapeutics, Inc. entered into Warrant Inducement Letter Agreement with an institutional investor valued at The Company agreed to issue warrants to purchase up to 3,964,712 shares of Common Stock at an exerci (effective 2026-01-15).
“On January 15, 2026, the Company entered into a warrant inducement letter agreement with the Holder (the “ Inducement Agreement ”) pursuant to which the Holder agreed to exercise for cash the entirety of the Warrants at a reduced exercise price of $2.34 per share (with such exercise price being established for purposes of compliance with the listing rules of the Nasdaq Stock Market), resulting in gross proceeds to the Company of approximately $4.6 million.”
Vivos Therapeutics, Inc. entered into Note with V-Co Investors 3 LLC valued at up to $5,500,000 (effective 2026-01-15).
“On January 15, 2026, Vivos Therapeutics, Inc. (the “ Company ”) entered into an unsecured convertible promissory note in favor of V-Co Investors 3 LLC (“ V-Co ”) in the maximum principal amount of up to $5,500,000 (the “ Note ” and the maximum principal amount, inclusive of the original issuance discount described below, the “ Maximum Principal ”).”
Vivos Therapeutics, Inc. incurred loan of $2,093,340 with Avondale Capital, LLC at does not bear interest maturing not stated.
“On December 5, 2025, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”) with from Avondale Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to Lender a Promissory Note (the “ Note ”) in the original principal amount of $2,093,340”
Vivos Therapeutics, Inc. completed an acquisition involving The Sleep Center of Nevada (SCN) (closed 2025-06-10).
“On June 10, 2025, the Company completed the Acquisition, and the Company had acquired all of the operating assets of the Seller in consideration for a (i) cash payment equal to $6.0 million, (ii) 607,287 shares of restricted common stock in the Company, par value $0.0001 per share (the “ Common Stock ”), equal to $1.5 million based on the volume-weighted average price (“ VWAP ”) of the Common Stock for the 30 days immediately preceding the Acquisition and (iii) the assumption of certain specific trade accounts payable and liabilities related to specific SCN contracts assigned to the Company as part of the Acquisition.”
Vivos Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.
“the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm”
Moss Adams LLP resigned as auditor of Vivos Therapeutics, Inc..
“(the “Company”) was formally notified that Moss Adams LLP (“Moss Adams”), the Company’s independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025.”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“rch 31, 2024) being less than $2.5 million. The Notice also indicated that Nasdaq would commence delisting proceedings against the Company. The Company has the right to, and has already filed for, an appeal the Nasdaq staff’s determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, to request an additional hearing on this matter before the Hearing Panel. The Company’s appeal has stayed any delisting or suspension action by the Nasdaq staff pending the issuance of the Hearing’s Panel decision. The Company’s common stock will remain listed on Nasdaq, pending th”
Vivos Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.4 million.
“Revenue was $3.4 million for the first quarter of 2024, compared to $3.8 million for the first quarter of 2023”
Vivos Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
“On March 28, 2024, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.